Latest News Archive
Please select Category, Year, and then Month to display items
26 July 2022
|
Story Bulelwa Moikwatlhai
|
Photo Supplied
Experiencing the UFS in person for the first time are from the left: Sandor Potjer (VU Amsterdam), Bulelwa Moikwatlhai (UFS OIA), Ricarda Kochems (Bremen University, Germany), Froukje Pronk (VU Amsterdam) and Matome Mokoena (UFS OIA)
As the UFS COVID-19 Regulations and Required Vaccination Policy has been lifted with immediate effect – allowing 100% capacity of both students and staff members and a fully operational campus – the
Office for International Affairs welcomes its first physical exchange cohort after two years. The cohort of students hail from the various international partners of the UFS, namely the
University of Bremen in Germany, the Vrije Universiteit Amsterdam, and Sciences PO Bordeaux in France. The students will be hosted in the UFS faculties of the Humanities, Economic and Management Sciences, and Natural and Agricultural Sciences, respectively.
These students have been paired with
Umoja Buddy Programme ambassadors to help ensure their smooth transition and integration into student life at the UFS. Furthermore, the students received an invitation from the President of the
International Student Association (ISA), Courtney Madziwa, to join their association, thus exposing them to students from other countries to learn about the various cultures.
On 18 July, the Office for International Affairs (OIA) arranged a hybrid orientation programme for the exchange students, including those students who have not yet arrived on the Bloemfontein Campus. The students took part in an icebreaker activity, where they had the opportunity to learn from and teach other participants about their home countries. Dr Cornelius Hagenmeier, Director of the OIA, welcomed the exchange students to the Bloemfontein Campus, and expressed excitement to have physical exchanges again. Furthermore, the guest presenters ranged from student leadership, staff members, and service providers.
The presentations were practical, demonstrating, among others, how to create a password on the institutional website – presented by Mr Molemo Mohapi from UFS ICT. The presentation on how to fully utilise Blackboard was facilitated by Ms Vuthihi Mudau from the UFS CTL division. We take the safety of all our students seriously, so Ms Elise Oberholzer from the UFS Protection Services has given the students some tips on how to safeguard themselves.
UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08
The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.
The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.
The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.
“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.
“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.
According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.
The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.
According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.
The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.
Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004